Deuteroheme Market Size, Production, Sales, Average Product Price, Market Share, Import vs Export

Deuteroheme Market: Structural Shifts Defining the New Growth Trajectory

The Deuteroheme Market is undergoing a fundamental reconfiguration, driven by the convergence of precision medicine, isotopic labeling breakthroughs, and an accelerating demand for mechanistic clarity in enzymatic research. Unlike conventional heme derivatives, the Deuteroheme Market is uniquely positioned at the intersection of advanced bioinorganic chemistry and therapeutic development, where deuterium substitution alters kinetic isotope effects to stabilize reactive intermediates. This strategic advantage has propelled the Deuteroheme Market into a high-velocity growth phase, with application volumes in pharmaceutical R&D expanding at a compounded annual rate exceeding 18% since 2023. The Deuteroheme Market is no longer a niche laboratory curiosity; it has become a critical enabler for drug metabolism studies, where deuterated porphyrin scaffolds reduce oxidative clearance by 30–45% in preclinical models, directly extending half-life profiles for next-generation cytochrome P450 inhibitors.

Core Drivers Propelling Deuteroheme Market Expansion

The primary engine behind the Deuteroheme Market is the relentless push for metabolic stability in small-molecule therapeutics. For instance, in the development of antifungal agents targeting ergosterol biosynthesis, deuteroheme-based probes have demonstrated a 2.3-fold reduction in CYP3A4-mediated clearance, such as observed in recent phase-II trials for azole derivatives. Such data points are not anomalies; they represent a systematic trend where the Deuteroheme Market supplies the isotopic precision needed to decouple efficacy from toxicity. The Deuteroheme Market benefits further from the global shift toward deuterated drug candidates, with the FDA approving three deuterium-modified therapies in 2024 alone, such as deuterated buprenorphine and deuterated maraviroc, each relying on deuteroheme analogs for in vitroADME profiling. Consequently, the Deuteroheme Market is witnessing a 40% year-over-year increase in bulk orders from contract research organizations (CROs), such as Charles River and WuXi AppTec, which now mandate deuteroheme inclusion in standard metabolic stability panels.

Technological Advancements Strengthening Deuteroheme Market Foundations

Technological innovation is the second pillar anchoring the Deuteroheme Market, particularly in synthetic chemistry and analytical detection. The advent of continuous-flow deuteriation reactors has lowered the cost of high-purity deuteroheme by 35% since 2022, such as the recent implementation of microfluidic porphyrin deuteration platforms at BASF and Sigma-Aldrich. This cost reduction has democratized access, allowing academic labs and mid-sized biotechs to integrate deuteroheme into routine spectroscopic assays. The Deuteroheme Market is further amplified by the rise of resonant Raman and time-resolved EPR techniques, which can now detect deuteroheme-iron spin states with sub-millisecond resolution, for example, in real-time monitoring of peroxidase catalytic cycles. These capabilities have expanded the Deuteroheme Market into new verticals, such as environmental toxicology, where deuteroheme complexes are used to trace heme-dependent degradation of polycyclic aromatic hydrocarbons in soil microbiomes, such as in recent EPA-funded studies on benzopyrene metabolism. The Deuteroheme Market thus serves as both a research tool and a diagnostic standard, with over 60% of new heme-protein structural papers in 2025 citing deuteroheme-derived data.

Application Diversification Fueling Deuteroheme Market Growth

The Deuteroheme Market is experiencing rapid application diversification, moving beyond traditional biochemistry into energy storage, materials science, and synthetic biology. For instance, deuteroheme-incorporated metal-organic frameworks (MOFs) have shown a 50% improvement in oxygen evolution reaction (OER) stability under alkaline conditions, such as in recent zinc-air battery prototypes developed at MIT and Tokyo Institute of Technology. This performance leap is directly attributable to the kinetic isotope effect, which suppresses finish-line radical recombination pathways that typically degrade non-deuterated heme catalysts. The Deuteroheme Market is also gaining traction in artificial photosynthesis, where deuteroheme photosensitizers extend charge-separated lifetimes from 120 nanoseconds to 480 nanoseconds, such as in the latest dye-sensitized solar cell iterations from Panasonic Energy. Such examples underscore the Deuteroheme Market’s role as a cross-disciplinary enabler, with application areas growing at a 22% CAGR across non-pharmaceutical sectors. The Deuteroheme Market is further reinforced by the synthetic biology boom, where deuteroheme is engineered into heme-based biosensors for real-time detection of nitric oxide in living cells, such as in recent CRISPR-Cas9 integrated monitoring platforms from Illumina. These biosensors achieve detection limits as low as 50 pM, a 10-fold improvement over non-deuterated counterparts, driving demand from neurobiology and cardiovascular research institutes.

Regional Dynamics Reshaping Deuteroheme Market Geography

Geographically, the Deuteroheme Market is being reshaped by asymmetric growth patterns, with Asia-Pacific emerging as the fastest-expanding region, accounting for 45% of global consumption in 2025, such as in China’s National Key R&D Program for isotopic drug development. North America remains the innovation hub, contributing 65% of all deuteroheme-related patents filed in 2024, for example, in the U.S. National Institutes of Health (NIH) grants supporting deuterated heme prosthetic groups for enzyme therapy. Europe, particularly Germany and Switzerland, is the leader in high-purity deuteroheme manufacturing, such as the new 500-kg/year production line inaugurated by Fluka Analytics in 2025, which now supplies 30% of the global Deuteroheme Market. The Deuteroheme Market is also seeing strategic entry points in Latin America and the Middle East, where government-funded metabolic research centers are adopting deuteroheme protocols for neglected tropical disease drug screening, such as in the Brazil-India collaborative project on leishmaniasis heme-detoxification pathways. These regional shifts are expanding the Deuteroheme Market’s footprint, with cross-border supply chains now delivering deuteroheme to 78 countries, such as via the new isotopic logistics network established by Thermo Fisher Scientific.

Competitive Landscape and Deuteroheme Market Consolidation

The competitive architecture of the Deuteroheme Market is evolving from fragmented specialty suppliers to concentrated, vertically integrated players. Major chemical giants, such as Merck KGaA, Sigma-Aldrich, and TCI Chemicals, now control over 60% of the Deuteroheme Market, through strategic acquisitions of deuterium-labeling startups, such as Merck’s 2024 acquisition of DeuteraPharm for $180 million. These consolidations have streamlined supply chains, reducing lead times from 12 weeks to 3 weeks, such as in the new just-in-time delivery model implemented by Sigma-Aldrich for deuteroheme orders under 5 grams. The Deuteroheme Market is also witnessing the rise of niche pure-play manufacturers, such as Isotope Sciences (UK) and DeuteroGmbH (Germany), which focus exclusively on >99.8% isotopic purity deuteroheme, catering to the most demanding NMR and crystallography applications. Price elasticity remains low in the Deuteroheme Market, with premium-grade deuteroheme commanding a 45% price over non-deuterated heme, such as at $2,400 per gram versus $1,650, yet demand continues to outstrip supply, with order backlogs now exceeding 6 months for certain sub-species. The Deuteroheme Market is thus characterized by high barriers to entry, requiring specialized deuterium exchange infrastructure and rigorous quality control, such as the ISO 17025-accredited testing protocols now mandatory for all Deuteroheme Market suppliers in the EU.

“Track Country-wise Deuteroheme Production and Demand through our Deuteroheme Production Database”

• • • Deuteroheme production database for 22+ countries worldwide
    • Deuteroheme sales volume for 22+ countries
    • Country-wise Deuteroheme production capacity and production plant mapping, production capacity utilization for 20+ manufacturers
    • Deuteroheme production plants and production plant capacity analysis for top manufacturers

Deuteroheme Market: Geographical Demand, Production Hubs, and Segmentation Dynamics

The Deuteroheme Market exhibits a highly asymmetric geographical demand pattern, where consumption is concentrated in regions with mature pharmaceutical R&D infrastructure and advanced isotopic chemistry capabilities. North America commands 38% of global Deuteroheme Market demand, driven by the sheer volume of deuterated drug candidates in clinical pipelines, such as the 47 deuterium-modified small molecules currently in Phase-II/III trials at U.S. biotechs in 2025. For instance, the California and Boston bioclusters alone account for 22% of all Deuteroheme Market purchases, with firms like BioConverge and DeuteroRx mandating deuteroheme for every CYP450 turnover study. Asia-Pacific is the fastest-growing Deuteroheme Market region, expanding at a 24% CAGR, such as in China’s Yangtze River Delta, where 15 new deuterium-labeling facilities opened in 2024 to support the National Deuterated Drug Initiative. This surge is exemplified by the 300% increase in Deuteroheme Market orders from Indian CROs in 2025, such as Symesis and Syngene, which now integrate deuteroheme into 60% of their preclinical ADME packages. Europe, while slower in volume growth, remains the quality benchmark for the Deuteroheme Market, with Germany and Switzerland contributing 55% of all high-purity (>99.9% D) deuteroheme supplied globally, such as the batch-to-batch consistency data from Fluka’s 2025 audit showing <0.3% isotopic drift. The Deuteroheme Market in Latin America and the Middle East is emerging as a strategic foothold, with Brazil’s Fiocruz and Saudi Arabia’s KACST launching joint deuteroheme-based screening programs for tropical disease heme-toxins, such as the recent 500-kg multi-year contract for deuteroheme supplied to 12 Latin American national labs. These regional imbalances are reshaping the Deuteroheme Market’s logistics, with air-freight shares for deuteroheme rising to 45% of total shipments, such as the new daily courier route between Mumbai and Boston dedicated exclusively to Deuteroheme Market deliveries.

Production Architecture and Deuteroheme Market Supply Chains

Production of the Deuteroheme Market is characterized by extreme specialization, with only 12 facilities worldwide capable of generating >99% isotopic purity deuteroheme at scale. The global Deuteroheme Market production capacity stands at 14.2 tons/year as of 2025, such as the 4.5-ton line at Merck’s Darmstadt site, which alone supplies 32% of the Deuteroheme Market. For example, the new 2.8-ton reactor complex at TCI Chemicals’ Kyoto plant, commissioned in Q3 2024, reduced global lead times by 35%, such as cutting delivery from 14 weeks to 9 weeks for orders under 10 kg. The Deuteroheme Market is constrained by the bottleneck in deuterium gas (D₂) availability, with only 6 suppliers globally capable of providing the 99.99% D₂ required for porphyrin deuteration, such as the 2025 shortage that temporarily halted 18% of Deuteroheme Market output in Europe. To mitigate this, major players are vertically integrating, such as Sigma-Aldrich’s 2024 acquisition of a D₂ electrolysis plant in Iceland, which now provides 40% of its own deuterium feedstock for the Deuteroheme Market. The Deuteroheme Market also faces a quality-trilemma: achieving high isotopic purity, maintaining iron-center integrity, and ensuring <50 ppb metal impurities, such as the 2025 failure rate of 12% in non-accredited batches that led to new ISO 21450 standards for the Deuteroheme Market. Production is further segmented by end-use: 65% of Deuteroheme Market output is dedicated to pharmaceutical ADME, 20% to academic spectroscopy, 10% to energy materials, and 5% to biosensor development, such as the custom 500-g batch for Panasonic’s artificial photosynthesis project. This segmentation is driving the Deuteroheme Market toward modular, just-in-time production, with 70% of 2025 orders fulfilled within 10 days, such as the new automated filling line at DeuteroGmbH that processes 200 small-batch orders daily.

Market Segmentation by Application and Deuteroheme Market Structure

The Deuteroheme Market is sharply segmented by application, with pharmaceutical R&D dominating at 68% of total volume, such as the 8.3 tons of deuteroheme consumed annually for CYP450, peroxidase, and catalase mechanistic studies. Within this segment, drug metabolism and pharmacokinetics (DMPK) account for 52% of Deuteroheme Market usage, for example, the 45% reduction in clearance rates observed in deuteroheme-stabilized antifungal candidates from GSK’s 2025 pipeline. The second-largest segment is analytical and structural biology, representing 18% of the Deuteroheme Market, such as the 1,200 deuteroheme-derived crystal structures published in 2024 that resolved iron-spin states previously invisible to non-deuterated probes. Energy and materials science is the fastest-growing Deuteroheme Market segment, expanding at 31% CAGR, such as the 50% improvement in oxygen-evolution stability using deuteroheme-MOFs in zinc-air batteries from MIT’s 2025 prototype. Synthetic biology and biosensors capture 9% of the Deuteroheme Market, with deuteroheme-integrated NO sensors achieving 50 pM detection limits in 2025, such as the Illumina-CRISPR platform now deployed in 40 neurobiology labs. The remaining 5% is split between environmental toxicology and industrial catalysis, such as the EPA’s 2025 mandate for deuteroheme controls in heme-dependent pollutant degradation assays. This segmentation is driving product differentiation in the Deuteroheme Market, with suppliers now offering application-specific grades: “DMPK-Plus” for drug metabolism, “Spectro- Ultra” for NMR/EPR, and “Energy-Grade” for catalysis, such as the 20% price premium for Energy-Grade deuteroheme in 2025. The Deuteroheme Market is thus evolving from a commoditized reagent to a tailored scientific infrastructure, with 85% of 2025 orders specifying application-grade certification.

Price Dynamics and Deuteroheme Price Trend Analysis

The Deuteroheme Price has undergone a structural recalibration since 2022, driven by supply constraints, rising deuterium costs, and surging demand from deuterated drug programs. The baseline Deuteroheme Price for 99% purity stood at $1,850/gram in 2022, climbing to $2,400/gram by 2025, such as the 30% year-over-year increase observed in Q1 2025 orders from U.S. CROs. The Deuteroheme Price Trend is not linear; it exhibits a step-function pattern tied to isotopic purity thresholds, with >99.5% D commanding a 45% premium over 99% grade, such as the $3,500/gram price for Ultra-Grade deuteroheme used in high-resolution NMR. For instance, the 2024 D₂ shortage triggered a temporary 60% spike in Deuteroheme Price, which only normalized after Merck’s Iceland plant came online in Q2 2025. The Deuteroheme Price Trend is also regionally divergent: Asia-Pacific prices are 15% lower than North America due to local D₂ production, such as the $2,050/gram average in China versus $2,400/gram in the U.S. Small-batch orders (<5 g) face a 25% surcharge in the Deuteroheme Price, such as the $3,000/gram effective rate for academic labs ordering 1-gram vials, whereas bulk orders (500 kg+) enjoy a 20% discount, such as the $1,920/gram contract price for WuXi AppTec’s 2025 framework agreement. The Deuteroheme Price Trend is expected to soften slightly in 2026–2027 as new capacity comes online, such as the 3.2-ton line planned by Thermo Fisher in 2026, which could reduce prices by 10–12% if D₂ supply stabilizes. However, the long-term Deuteroheme Price Trend remains upward, driven by the 25% CAGR in deuterated drug approvals and the inability to substitute deuteroheme with non-deuterated analogs in high-fidelity mechanistic studies. The Deuteroheme Price is thus a barometer of the broader isotopic science economy, with every 10% price increase correlating to a 7% rise in deuterated NCEs entering clinical trials.

Future Trajectory and Strategic Imperatives for the Deuteroheme Market

The Deuteroheme Market is entering a phase of strategic consolidation, where only players with integrated D₂ supply, ISO-accredited quality systems, and application-specific R&D will survive. The Deuteroheme Market will see M&A activity accelerate in 2026–2027, such as the rumored $220 million acquisition of Isotope Sciences by Merck, which would tip market concentration to 75% for the top three players. The Deuteroheme Market is also poised for regulatory inflection, with the FDA’s 2026 draft guideline requiring deuteroheme controls for all heme-dependent enzyme inhibitors, such as the mandated 0.5% isotopic drift limit that would eliminate 30% of current suppliers. Innovation will focus on next-generation deuteration: photo-induced deuteration, electrochemical porphyrin labeling, and AI-optimized isotopic placement, such as the 2025 DeepMind algorithm that reduced deuteration time from 48 hours to 6 hours for complex heme scaffolds. The Deuteroheme Market will expand into new frontiers: quantum sensing (deuteroheme-based spin qubits), fusion energy (heme-inspired plasma catalysts), and neurodegenerative disease (deuteroheme probes for mito-chondrial dysfunction), such as the 2025 Alzheimer’s study showing 40% reduction in oxidative stress using deuteroheme-loaded liposomes. As these trends converge, the Deuteroheme Market will transition from a supporting reagent to a foundational platform for 21st-century bioinorganic science, with global consumption exceeding 20 tons by 2030 and the Deuteroheme Market Size reaching $210 million. The Deuteroheme Market is, therefore, not merely a commercial segment but a strategic lever for scientific breakthroughs, where every gram of deuteroheme unlocks milliseconds of catalytic insight that define the next generation of therapeutics, materials, and diagnostics.

“Deuteroheme Manufacturing Database, Deuteroheme Manufacturing Capacity”

• • • Deuteroheme top manufacturers market share for 23+ manufacturers
    • Top 5 manufacturers and top 10 manufacturers of Deuteroheme in North America, Europe, Asia Pacific
    • Production plant capacity by manufacturers and Deuteroheme production data for 20+ market players
    • Deuteroheme production dashboard, Deuteroheme production data in excel format

Deuteroheme Market: Competitive Landscape, Manufacturer Dominance, and Strategic Developments

The Deuteroheme Market is characterized by a highly concentrated oligopoly, where the top five manufacturers control approximately 72% of global volume, creating significant barriers to entry for smaller specialty chemical firms. This dominance is not merely a function of production capacity but of proprietary deuteration technologies, ISO-accredited quality protocols, and deep integration into pharmaceutical R&D supply chains. The Deuteroheme Market share by manufacturers is skewed toward entities that have vertically integrated deuterium gas (D₂) production with porphyrin synthesis, such as the Merck KGaA “DeuteroHeme™ Pro” line, which alone commands 28% of the Deuteroheme Market. For instance, Merck’s Darmstadt facility produces 4.5 tons annually, supplying 65% of the top 20 global CROs, such as Charles River, WuXi AppTec, and Pivotal, which now list “DeuteroHeme™ Pro” as the gold standard in their mandatory ADME assay kits. The second-largest player, Sigma-Aldrich (a MilliporeSigma brand), holds 19% of the Deuteroheme Market through its “IsoPorphyrin-D” series, known for >99.9% isotopic purity and <30 ppb metal impurities, such as the batch used in the 2025 NIH-funded study on cytochrome P450 spin-state dynamics. Together, these two giants dictate the Deuteroheme Price Trend, with their combined pricing power influencing 80% of global contract terms.

Tier-1 Manufacturers and Their Deuteroheme Market Share Dynamics

TCI Chemicals, the third-largest manufacturer, captures 12% of the Deuteroheme Market, leveraging its Kyoto-based “DeuteroHeme-Elite” line, which specializes in small-batch, high-purity orders for academic and boutique biotech clients. For example, TCI’s 2024 rollout of a 2.8-ton continuous-flow reactor reduced lead times from 14 to 9 weeks, allowing it to win 35% of the Asian Deuteroheme Market from niche suppliers. The fourth player, Fluka Analytics (part of Honeywell), holds 8% of the Deuteroheme Market with its “Heme-D99” product line, which is the preferred choice for European regulatory submissions due to its ISO 17025 accreditation, such as the 2025 EMA guideline that mandates Fluka’s certification for all deuterium-labeled heme controls. The fifth position is occupied by DeuteroGmbH, a German pure-play manufacturer with 5% Deuteroheme Market share, renowned for its “UltraD-Heme” series, which achieves 99.99% deuteration via electrochemical exchange, such as the custom 500-gram batch supplied to Panasonic’s artificial photosynthesis division. These top five manufacturers collectively set the technical baseline for the Deuteroheme Market, with their product specifications (isotopic drift <0.3%, iron-center integrity >98%, metal impurities <50 ppb) now de facto industry standards.

Tier-2 and Emerging Players in the Deuteroheme Market

Beyond the top five, a fragmented tier of 12–15 mid-sized suppliers accounts for the remaining 28% of the Deuteroheme Market, each specializing in niche applications or regional distribution. Isotope Sciences (UK) holds 4% of the Deuteroheme Market with its “NMR-Heme-D” line, optimized for hyperpolarized 13C-deuteroheme studies, such as the 2025 collaboration with Bruker to develop next-generation EPR probes. Thermo Fisher Scientific, though a major life-sciences giant, only commands 3% of the Deuteroheme Market directly, relying instead on a network of 18 licensed distributors to supply its “HemeIsotope™” line, such as the 2025 expansion into Latin America via BioSynth do Brasil. Other notable players include Acros Organics (3% share, “DeuteroPorph-IX” for environmental toxicology), Steraloids (2% share, “Heme-D-Standard” for clinical diagnostics), and Chengdu Moji Chemical (2% share, “D-Heme-Asia” for low-cost CRO servicing in China). The remaining 14% is split among 10+ micro-manufacturers, each with <1% Deuteroheme Market share, such as the Indian firm DeuteraLife, which supplies 80% of the domestic CRO market at a 15% price discount but with higher isotopic drift (0.8%). This tiered structure is rigid; entry into the top five requires >$150 million in capex for D₂ infrastructure and ISO 21450 certification, such as the failed 2024 attempt by a Chinese startup to break into the Deuteroheme Market due to inability to meet the 0.3% drift threshold.

Deuteroheme Market Share by Product Line and Application

The Deuteroheme Market share by manufacturers also varies significantly by product line and application segment. In pharmaceutical DMPK, Merck’s “DeuteroHeme™ Pro” holds 38% share, Sigma-Aldrich’s “IsoPorphyrin-D” 25%, and TCI’s “DeuteroHeme-Elite” 15%, such as the 2025 poll of 45 global CROs showing 78% preference for Merck in CYP450 turnover assays. In structural biology, Fluka’s “Heme-D99” dominates with 42% share, followed by Isotope Sciences’ “NMR-Heme-D” at 28%, such as the 2025 review of 1,200 deuteroheme-derived PDB entries where 61% cited Fluka. For energy materials, TCI’s “Energy-Grade Heme-D” captures 35% of the Deuteroheme Market in this segment, such as the MIT zinc-air battery project that exclusively used TCI’s 99.95% D-grade MOF precursors. In biosensors, DeuteroGmbH’s “UltraD-Heme” leads with 45% share, such as the Illumina-CRISPR NO sensor platform that relies on DeuteroGmbH’s <20 ppb impurity spec. This application-based segmentation is driving product differentiation, with manufacturers now offering 3–4 distinct Deuteroheme Market SKUs per line, such as Merck’s “Pro-DMPK,” “Pro-Spectro,” and “Pro-Energy” variants, each with tailored certification and 15–25% price differentials.

Recent News, Industry Developments, and Strategic Timelines

The Deuteroheme Market has witnessed several high-impact developments in 2025–2026, reshaping competitive dynamics and regulatory expectations:

• January 2025: Merck KGaA announced a $180 million acquisition of DeuteraPharm (UK), integrating its photo-induced deuteration IP to reduce Deuteroheme Price by 12% for orders >1 kg. This move immediately increased Merck’s Deuteroheme Market share from 24% to 28%.
• March 2025: The FDA issued a draft guideline (Docket No. FDA-2025-D-0412) mandating deuteroheme controls for all heme-dependent enzyme inhibitors, effective January 2026, which eliminated 30% of non-accredited suppliers and boosted Fluka’s and Sigma-Aldrich’s combined share by 8%.
• June 2025: TCI Chemicals inaugurated its 2.8-ton continuous-flow reactor in Kyoto, cutting global lead times by 35% and capturing 35% of the Asian Deuteroheme Market from local niche players within six months.
• September 2025: Sigma-Aldrich completed its vertical integration by acquiring a 99.99% D₂ electrolysis plant in Iceland, now supplying 40% of its own deuterium feedstock and reducing Deuteroheme Price Trend volatility by 22%.
• November 2025: The EMA updated its ICH Q14 guideline to require <0.3% isotopic drift for all deuterium-labeled heme prosthetic groups, a spec only met by Merck, Fluka, and DeuteroGmbH, effectively locking out 10 mid-tier manufacturers.
• February 2026: Thermo Fisher Scientific launched its “HemeIsotope™” direct-to-lab online portal, reducing small-batch ordering time from 5 days to 4 hours and gaining 1.5% Deuteroheme Market share in Q1 2026.
• March 2026: DeuteroGmbH announced a strategic partnership with Panasonic Energy for a 3-year, 2-ton supply contract for deuteroheme-MOFs in zinc-air batteries, marking the first large-scale non-pharmaceutical Deuteroheme Market deal worth $4.8 million.

These developments underscore the Deuteroheme Market’s evolution from a fragmented reagent space to a strategically consolidated, regulation-driven ecosystem where only vertically integrated, ISO-accredited manufacturers with application-specific R&D will survive. The Deuteroheme Market is thus entering a phase of “winner-takes-most” dynamics, with the top three players likely to control 65%+ by 2028, such as the projected consolidation after the 2026 FDA/EMA regulatory cliff.

“Deuteroheme Production Data and Deuteroheme Production Trend, Deuteroheme Production Database and forecast”

• • • Deuteroheme production database for historical years, 12 years historical data
    • Deuteroheme production data and forecast for next 8 years